[1]CurrentPatentAssignee:BEIGENELTD.-WO2013/97225,2013,A1
[2]CurrentPatentAssignee:BEIGENELTD.-US2015/175617,2015,A1
[3]CurrentPatentAssignee:BEIGENELTD.-JP2017/48214,2017,A
[4]CurrentPatentAssignee:BEIGENELTD.-TWI633107,2018,B
[5]Wang,Hexiang;Ren,Bo;Liu,Ye;Jiang,Beibei;Guo,Yin;Wei,Min;Luo,Lusong;Kuang,Xianzhao;Qiu,Ming;Lv,Lei;Xu,Hong;Qi,Ruipeng;Yan,Huibin;Xu,Dexu;Wang,Zhiwei;Huo,Chang-Xin;Zhu,Yutong;Zhao,Yuan;Wu,Yiyuan;Qin,Zhen;Su,Dan;Tang,Tristin;Wang,Fan;Sun,Xuebing;Feng,Yingcai;Peng,Hao;Wang,Xing;Gao,Yajuan;Liu,Yong;Gong,Wenfeng;Yu,Fenglong;Liu,Xuesong;Wang,Lai;Zhou,Changyou[JournalofMedicinalChemistry,2020,vol.63,#24,p.15541-15563]
[1]CurrentPatentAssignee:BEIGENELTD.-WO2013/97225,2013,A1
[2]CurrentPatentAssignee:BEIGENELTD.-US2015/175617,2015,A1
[3]CurrentPatentAssignee:BEIGENELTD.-JP2017/48214,2017,A
[4]CurrentPatentAssignee:BEIGENELTD.-TWI633107,2018,B
[5]Wang,Hexiang;Ren,Bo;Liu,Ye;Jiang,Beibei;Guo,Yin;Wei,Min;Luo,Lusong;Kuang,Xianzhao;Qiu,Ming;Lv,Lei;Xu,Hong;Qi,Ruipeng;Yan,Huibin;Xu,Dexu;Wang,Zhiwei;Huo,Chang-Xin;Zhu,Yutong;Zhao,Yuan;Wu,Yiyuan;Qin,Zhen;Su,Dan;Tang,Tristin;Wang,Fan;Sun,Xuebing;Feng,Yingcai;Peng,Hao;Wang,Xing;Gao,Yajuan;Liu,Yong;Gong,Wenfeng;Yu,Fenglong;Liu,Xuesong;Wang,Lai;Zhou,Changyou[JournalofMedicinalChemistry,2020,vol.63,#24,p.15541-15563]
[1]CurrentPatentAssignee:BEIGENELTD.-WO2013/97225,2013,A1
[2]CurrentPatentAssignee:BEIGENELTD.-US2015/175617,2015,A1
[3]CurrentPatentAssignee:BEIGENELTD.-JP2017/48214,2017,A
[4]CurrentPatentAssignee:BEIGENELTD.-TWI633107,2018,B
[5]Wang,Hexiang;Ren,Bo;Liu,Ye;Jiang,Beibei;Guo,Yin;Wei,Min;Luo,Lusong;Kuang,Xianzhao;Qiu,Ming;Lv,Lei;Xu,Hong;Qi,Ruipeng;Yan,Huibin;Xu,Dexu;Wang,Zhiwei;Huo,Chang-Xin;Zhu,Yutong;Zhao,Yuan;Wu,Yiyuan;Qin,Zhen;Su,Dan;Tang,Tristin;Wang,Fan;Sun,Xuebing;Feng,Yingcai;Peng,Hao;Wang,Xing;Gao,Yajuan;Liu,Yong;Gong,Wenfeng;Yu,Fenglong;Liu,Xuesong;Wang,Lai;Zhou,Changyou[JournalofMedicinalChemistry,2020,vol.63,#24,p.15541-15563]
[1]CurrentPatentAssignee:BEIGENELTD.-WO2013/97225,2013,A1
[2]CurrentPatentAssignee:BEIGENELTD.-US2015/175617,2015,A1
[3]CurrentPatentAssignee:BEIGENELTD.-JP2017/48214,2017,A
[4]CurrentPatentAssignee:BEIGENELTD.-TWI633107,2018,B
[5]Wang,Hexiang;Ren,Bo;Liu,Ye;Jiang,Beibei;Guo,Yin;Wei,Min;Luo,Lusong;Kuang,Xianzhao;Qiu,Ming;Lv,Lei;Xu,Hong;Qi,Ruipeng;Yan,Huibin;Xu,Dexu;Wang,Zhiwei;Huo,Chang-Xin;Zhu,Yutong;Zhao,Yuan;Wu,Yiyuan;Qin,Zhen;Su,Dan;Tang,Tristin;Wang,Fan;Sun,Xuebing;Feng,Yingcai;Peng,Hao;Wang,Xing;Gao,Yajuan;Liu,Yong;Gong,Wenfeng;Yu,Fenglong;Liu,Xuesong;Wang,Lai;Zhou,Changyou[JournalofMedicinalChemistry,2020,vol.63,#24,p.15541-15563]
[1]CurrentPatentAssignee:BEIGENELTD.-WO2013/97225,2013,A1
[2]CurrentPatentAssignee:BEIGENELTD.-US2015/175617,2015,A1
[3]CurrentPatentAssignee:BEIGENELTD.-JP2017/48214,2017,A
[4]CurrentPatentAssignee:BEIGENELTD.-TWI633107,2018,B
[5]Wang,Hexiang;Ren,Bo;Liu,Ye;Jiang,Beibei;Guo,Yin;Wei,Min;Luo,Lusong;Kuang,Xianzhao;Qiu,Ming;Lv,Lei;Xu,Hong;Qi,Ruipeng;Yan,Huibin;Xu,Dexu;Wang,Zhiwei;Huo,Chang-Xin;Zhu,Yutong;Zhao,Yuan;Wu,Yiyuan;Qin,Zhen;Su,Dan;Tang,Tristin;Wang,Fan;Sun,Xuebing;Feng,Yingcai;Peng,Hao;Wang,Xing;Gao,Yajuan;Liu,Yong;Gong,Wenfeng;Yu,Fenglong;Liu,Xuesong;Wang,Lai;Zhou,Changyou[JournalofMedicinalChemistry,2020,vol.63,#24,p.15541-15563]
Title: Changyou Zhou, et al. Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors. WO 2013097225 A1.
Title: Friedlander M, et al. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial. Lancet Oncol. 2019 Sep;20(9):1306-1315.
Title: Zhiyu Tang, et al. Abstract 1653: BGB-290: A highly potent and specific PARP1/2 inhibitor potentiates anti-tumor activity of chemotherapeutics in patient biopsy derived SCLC models. Cancer Research. August 2015, Volume 75, Issue 15.
Title: Shiv K. Gupta, et al. Abstract 3505: Inhibition of PARP activity by BGB-290 potentiates efficacy of NSC 362856 in patient derived xenografts of glioblastoma multiforme. Cancer Research. August 2015, Volume 75, Issue 15